- Home
- IMNN
IMNN
Imunon Inc.
as 07-04-2025 12:33pm EST
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | LAWRENCEVILLE |
| Market Cap: | 12.1M | IPO Year: | 1985 |
| Target Price: | $14.00 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.37 - $3.65 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Imunon Inc. News
IMNN Breaking Stock News: Dive into IMNN Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
12 days ago
OTC Markets Hosts Virtual Investor Presentation with Stacy Lindborg, President, CEO, and Board Director of Imunon, and David Bautz, PhD, Senior Analyst at Zacks SCR
Zacks Small Cap Research
17 days ago
IMNN: Translational Data from OVATION 2 Presented…
GlobeNewswire
19 days ago
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire
20 days ago
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
GlobeNewswire
24 days ago
Life Sciences Investor Forum: Now Available for Online Viewing
GlobeNewswire
a month ago
Life Sciences Investor Forum Agenda Announced for June 11th-12th
GlobeNewswire
a month ago
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
Clinical Trials Arena
a month ago
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
Compare IMNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNN Imunon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.